Finance | Danaher to Acquire Masimo for $9.9 Billion, Boosts Diagnostics
Senior Technology Correspondent · AI, startups & MeitY policy
Quick summary
Global science and technology innovator Danaher Corporation announced plans on , to acquire specialty diagnostics provider Masimo Corporation for approximately $9.9 billion. This acquisition aims to significantly strengthen Danaher's Diagnostics segment, though direct implications for Indian markets were not immediately detailed.
Danaher to Acquire Masimo Corporation for Approximately $9.9 Billion
Danaher Corporation, a global science and technology innovator, announced on , that it has entered into a definitive agreement to acquire Masimo Corporation, a prominent specialty diagnostics provider. The all-cash transaction is valued at approximately $9.9 billion, including assumed indebtedness, and aims to bolster Danaher’s Diagnostics segment.
Key Details of the Acquisition
Under the terms of the agreement, Danaher will acquire all outstanding shares of Masimo common stock for $180 per share in cash. Following the completion of the transaction, Masimo Corporation is expected to operate as a standalone company within Danaher’s existing Diagnostics segment, which includes other entities such as Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics. Danaher anticipates funding the acquisition using a combination of cash on hand and proceeds from debt financing. Financial advisors for the transaction included Citi for Danaher, with Goldman Sachs providing advisory support, while Kirkland & Ellis LLP served as legal advisor to Danaher.
Official Rationale and Strategic Fit
Rainer M. Blair, President and Chief Executive Officer of Danaher, stated that Masimo is an “exceptional strategic fit” for the company, highlighting its leadership in pulse oximetry and other patient monitoring solutions. This integration is expected to significantly strengthen Danaher’s diagnostics franchise. Julie Sawyer Montgomery, Executive Vice President for Diagnostics at Danaher, further emphasized that Masimo’s advanced sensor technology and AI-enabled monitoring will bring powerful new capabilities to Danaher’s diagnostics portfolio. Masimo CEO Katie Szyman commented that becoming part of Danaher would enhance their ability to scale monitoring technologies globally and accelerate their mission in patient care.
Market Reaction
Following the announcement, Masimo’s shares experienced a significant jump, rising over 34% on the Nasdaq stock exchange, trading around $175 per share, up from its previous closing price. This surge reflects the market's response to the acquisition premium.
Timeline and Next Steps
The acquisition is currently subject to customary closing conditions, including the receipt of applicable regulatory clearances and approval from Masimo shareholders. The companies anticipate the transaction to be finalized in the second half of 2026.
Context and Background
Danaher Corporation operates as a global science and technology innovator, with a broad portfolio across various segments. Masimo Corporation is recognized as a leading provider of specialty diagnostics, particularly known for its expertise in pulse oximetry and other patient monitoring solutions predominantly used in acute care settings.
KEY TAKEAWAYS
- Danaher Corporation plans to acquire Masimo Corporation for approximately $9.9 billion, or $180 per share in cash.
- The acquisition is expected to strengthen Danaher’s Diagnostics segment by integrating Masimo’s patient monitoring solutions.
- Masimo will operate as a standalone company within Danaher's Diagnostics segment post-acquisition.
- The transaction is anticipated to close in the second half of 2026, pending regulatory and shareholder approvals.
- Masimo's stock surged over 34% following the acquisition announcement.
PEOPLE ALSO ASK
What is the value of Danaher's acquisition of Masimo?
Danaher Corporation's acquisition of Masimo Corporation is valued at approximately $9.9 billion in cash, which includes assumed indebtedness. This amounts to $180 per share for all outstanding shares of Masimo common stock.
When is the Danaher-Masimo acquisition expected to close?
The acquisition of Masimo Corporation by Danaher Corporation is anticipated to close in the second half of 2026. This timeline is subject to customary conditions, including obtaining necessary regulatory clearances and Masimo shareholder approval.
Why is Danaher acquiring Masimo?
Danaher is acquiring Masimo to strengthen its Diagnostics segment. According to Danaher's CEO, the acquisition of Masimo, a leader in patient monitoring solutions, represents an "exceptional strategic fit" that will enhance Danaher's diagnostics franchise with advanced sensor technology and AI-enabled monitoring capabilities.
Will Masimo operate independently after the acquisition?
Yes, upon the completion of the acquisition, Masimo Corporation is expected to operate as a standalone business unit and brand within Danaher’s Diagnostics segment. It will maintain its autonomous operations while benefiting from Danaher's broader scale.
Last updated: